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World Restart a Heart 
initiative: all citizens of 
the world can save a life 
Sudden cardiac arrest is the third 
leading cause of death in industrial­
ised nations, resulting in more than 
700 000 deaths in Europe and the 
USA annually.1 After cardiac arrest, 
the brain can survive for 3–5 min, 
which could be the minimum time 
that emergency medical services take 
to arrive. Con sequently, the most 
important way to improve survival 
is the instigation of early bystand­
er cardiopulmonary resuscitation 
(CPR).2 Bystander CPR increases sur­
vival by two to four times, which is 
much better than with any other 
intervention by emergency medical 
services or hospital staff.2–4 This 
finding explains why the focus of 
successful management of people 
after cardiac arrest has shifted to 
the out­of­hospital setting.3,4 The 
proportion of cardiac arrests in 
which a bystander attempts CPR, 
however, differs substantially world­
wide, ranging from 5–20% in most 
countries to more than 60–80% in 
a few countries.3,5 If, in all coun tries, 
bystanders attempted CPR in at 
least 50% of cardiac arrests, hund­
reds of thousands of lives could be 
saved worldwide every year.4,5 To 
achieve this goal, the International 
Liaison Committee on Resuscitation 
launches the World Restart a Heart 
(WRAH) initiative on Oct 16, 2018, 
with the motto “All citizens of the 
world can save a life” (figure). With 
the WRAH initiative, the European 
Restart a Heart Day, which was 
established in 2012 by the European 
Resuscitation Council with the 
support of 400 Members of the 
European Parliament, goes global, 
whereas similar initiatives have 
been developed in parallel around 
the world.5 The primary goal of the 
WRAH initiative is to empower as 
many bystanders as possible, includ­
ing non­professionals, to do chest 
compressions. With the help of 
local, national, and international 
activities on and around Oct 16, 
2018, and in subsequent years, the 
message will go out to policy makers 
that all citizens of the world can 
indeed save a life, and that people 
should be equipped with the 
simple skills that are necessary to do 
this lifesaving act, ideally through 
man datory training programmes 
in schools.
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Prevalence and control 
of hypertension
Jiapeng Lu and colleagues (Dec 9, 
2017, p 2549)1 elegantly showed 
that uncontrolled blood pressure was 
highly prevalent in China, although 
re sources to control hypertension 
were limited.1 As in other studies 
assessing the prevalence of hyper­
tension,2 con trolled hypertension 
was defined as a blood pressure of 
140/90 mm Hg or more, irrespective of 
age and cardiovascular risk. However, 
several guidelines, including those 
from WHO, recommend prescribing 
a blood pressure­lowering treatment 
only if cardiovascular risk is high 
(eg, 10­year risk of fatal or non­
fatal cardiovascular event ≥20%) 
or blood pressure is very high (eg, 
≥160/100 mm Hg).2 When using an 
approach based on cardiovascular risk, 
many young or middle­aged adults 
(aged <40 years) with moderately 
increased blood pressure will not be 
eligible for antihypertensive medica­
tion. Hence, despite a blood pressure 
of 140/90 mm Hg or more, the 
hypertension in these people might 
not be considered uncontrolled. 
The prevalence of people elig ible 
for hypertension treatment, the 
pre valence of uncontrolled hyper­
tension, and the resources needed 
to treat hypertension will, therefore, 
largely differ depending on whether 
national guidelines advise treatment 
above a specific blood pressure (eg, 
≥140/90 mm Hg) or on the basis of 
cardiovascular risk.3,4 Irrespective of 
which strategy is best,5 we suggest that 
all studies reporting the prevalence 
of uncontrolled hypertension, and 
the resources needed to address 
the burden, explicitly state whether 
they refer to a risk factor approach, a 
cardiovascular risk approach, or a mix 
of both, to help interpret the results 
and better guide policy.
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Figure: The logo of the International Liaison 
Committee on Resuscitation World Restart a 
Heart initiative
This logo can and should be used for all associated 
activities around the world. 
For more on the 
WRAH initiative see 
http://www.ilcor.org/wrah
For more on European Restart a 
Heart Day see http://erc.edu/
about/restart
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of antihypertensive medication among 
patients with hypertension. We did not 
address the issue of the percentage of 
people who should be treated and were 
not. Such an assessment, as suggested, 
might use various approaches to deter­
mine eligibility for pharmacological 
treatment. For example, the Chinese 
guideline states that blood pressure, 
cardiovascular risk (eg, age, smoking, 
lipid profile, family history, etc), target­
organ damage (eg, left ventricular 
hypertrophy, abnormal ECG, increased 
artery intima­media thickness, etc), and 
complications (eg, stroke, myocardial 
infarction, kidney disease, etc) should 
be considered to decide the eligibility 
for antihypertension medications.3 
It is impractical to collect this many 
indicators from each participant, to 
assess the eligibility for treatment, in a 
large scale population­based screening 
study. However, we did highlight that 
many people treated with a single 
medication had blood pressures that 
were not considered controlled. Quality 
metrics that report undertreatment 
and overtreatment of hypertension 
are needed. These measures, as 
suggested, would need to incorporate 
consideration of the approach to 
defining the denomi nator of people 
who should receive treatment.
We declare no competing interests.
Jiapeng Lu, Yuan Lu, 
Harlan M Krumholz, *Lixin Jiang
jiangl@fwoxford.org
National Clinical Research Center of Cardiovascular 
Diseases, State Key Laboratory of Cardiovascular 
Disease, Fuwai Hospital, National Center for 
Cardiovascular Diseases, Chinese Academy of 
Medical Sciences and Peking Union Medical College, 
Beijing, China (JL, LJ); and Center for Outcomes 
Research and Evaluation, Yale University and 
Yale­New Haven Hospital, New Haven, Connecticut, 
USA (YL, HMK).
1 Lu J, Lu Y, Wang X, et al. Prevalence, awareness, 
treatment, and control of hypertension in 
China: data from 1·7 million adults in a 
population­based screening study (China 
PEACE Million Persons Project). Lancet 2017; 
390: 2549–58.
2 James PA, Oparil S, Carter BL, et al. 2014 
evidence­based guideline for the management 
of high blood pressure in adults: report from 
the panel members appointed to the Eighth 
Joint National Committee (JNC 8). JAMA 2014; 
311: 507–20.
3 Liu LS. 2010 Chinese guidelines for the 
management of hypertension. 
Zhonghua Xin Xue Guan Bing Za Zhi 2011; 
39: 579­615 (in Chinese).
VLCD for weight loss 
and remission of type 2 
diabetes?
In the DiRECT trial, Michael Lean and 
colleagues (Feb 10, p 541)1 report 
diabetes remission after very low 
calorie diets (VLCDs). Numerous 
studies of VLCDs have shown diabetes 
improvement and remission, but 
much of the effect, as this trial 
confirms, is correlated to weight 
loss.2 Unfortunately, weight loss 
from VLCD with behavioural therapy 
has proven to be unsustainable in 
1­year to 5­year follow­up studies.3 
Metabolic adaptation driving regain 
in response to caloric restriction is well 
documented, supporting the paradigm 
that weight regain after VLCD is 
more related to energy regulatory 
mechanisms than willpower.4,5 
Although the authors do not report 
the average percent regain, it can be 
estimated to be 20% (reported initial 
mean weight loss was 14·5 kg and 
mean regain at 1 year was 2·9 kg), 
calling into question the durability of 
the outcomes.
Given disease heterogeneity, there 
might be a subgroup of long­term VLCD 
responders that warrant phenotyping. 
Notably, study partici pants at baseline 
were non­insulin dependent, more than 
two­thirds were diet controlled or on 
mono therapy, and the mean HbA1c was 
7·7% or 60 mmol/mol. A comparison 
of responders to non­responders 
would help elucidate whether mild 
disease or use of glucagon­like 
peptide­1 agon ists or sodium­glucose 
co­transporter­2 inhibitors with known 
anti­obesity effects were related to 
remission. Previous studies have shown 
VLCD plus anti­obesity medication is 
superior to VLCD alone.6
Although the study’s 1­year results 
are confirmatory in their diabetes 
Authors’ reply
We appreciate the Correspondence 
by Pascal Bovet and Arnaud Chiolero 
about our study of the prevalence, 
aware ness, treatment, and control of 
hypertension in China.1 They suggest 
that for all studies reporting the 
prevalence of uncontrolled hyper­
tension, and the resources needed to 
address the burden, authors should 
explicitly state whether referring to a 
risk factor approach, a cardiovascular 
risk approach, or a mix of both so 
as to help interpret the results and 
guide policy.
As stated in the Methods section 
of our Article, we clearly defined con­
trolled and treated hypertension. 
Controlled hypertension was defined 
as an average systolic blood pressure of 
less than 140 mm Hg and an average 
diastolic blood pressure of less than 
90 mm Hg over two readings in people 
with hypertension, which is consistent 
with the definition in both the eighth 
Joint National Committee guideline2 
and Chinese guideline.3 Treated 
hypertension was defined as current use 
